Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2023-02-13 4:41 pm Purchase | 2022-12-31 | 13G | Duos Technologies Group, Inc. DUOT | Lytton, Laurence W. | 634,025 8.900% | 419,325 (+195.31%) | Filing History |
| 2023-02-13 4:31 pm Purchase | 2022-12-31 | 13G | Giga-tronics Incorporated GIGA | Lytton, Laurence W. | 603,700 9.990% | 328,749 (+119.57%) | Filing History |
| 2023-02-13 4:22 pm Purchase | 2022-12-31 | 13G | LiqTech International, Inc. LIQT | Lytton, Laurence W. | 566,679 9.990% | 290,432 (+105.14%) | Filing History |
| 2023-02-13 4:13 pm Purchase | 2022-12-31 | 13G | Scientific Industries, Inc. SCND | Lytton, Laurence W. | 590,208 8.300% | 181,979 (+44.58%) | Filing History |
| 2023-02-13 4:03 pm Sale | 2022-12-31 | 13G | TFF Pharmaceuticals, Inc. TFFP | Lytton, Laurence W. | 125,029 8.400% | -477 (-0.38%) | Filing History |
| 2023-02-13 3:54 pm Sale | 2022-12-31 | 13G | VERTEX ENERGY INC VTNRQ | Lytton, Laurence W. | 513,330 0.700% | -3,135,737 (-85.93%) | Filing History |
| 2023-02-13 3:47 pm Purchase | 2022-12-31 | 13G | Exagen Inc. XGN | Lytton, Laurence W. | 871,181 5.300% | 37,876 (+4.55%) | Filing History |
| 2023-02-13 3:40 pm Sale | 2022-12-31 | 13G | Paratek Pharmaceuticals, Inc. PRTK | Lytton, Laurence W. | 459,961 0.800% | -2,750,591 (-85.67%) | Filing History |
| 2023-02-13 3:33 pm Sale | 2022-12-31 | 13G | HTG Molecular Diagnostics, Inc. HTGM | Lytton, Laurence W. | 0 0.000% | -43,474 (Position Closed) | Filing History |
| 2023-02-13 3:24 pm Sale | 2022-12-31 | 13G | Apollo Endosurgery, Inc. APEN | Lytton, Laurence W. | 3,403,180 6.700% | -286,740 (-7.77%) | Filing History |
| 2023-02-13 3:14 pm Purchase | 2022-12-31 | 13G | Cellectar Biosciences, Inc. CLRB | Lytton, Laurence W. | 16,081 4.990% | 2,155 (+15.47%) | Filing History |
| 2023-02-13 2:55 pm Sale | 2022-12-31 | 13G | Crescent Biopharma, Inc. CBIO | Lytton, Laurence W. | 1,778 7.100% | -2,948 (-62.37%) | Filing History |
| 2023-02-10 7:02 pm Purchase | 2022-12-31 | 13G | EMCORE Corporation EMKR | Lytton, Laurence W. | 292,327 7.800% | 87,937 (+43.02%) | Filing History |
| 2023-01-19 6:34 pm Purchase | 2023-01-10 | 13G | BIOLASE, Inc. BIOL | Lytton, Laurence W. | 24,611 9.990% | 24,611 (New Position) | Filing History |
| 2022-11-23 2:40 pm Purchase | 2022-11-14 | 13G | Exagen Inc. XGN | Lytton, Laurence W. | 833,305 5.100% | 833,305 (New Position) | Filing History |
| 2022-11-23 1:01 pm Purchase | 2022-11-18 | 13G | TFF Pharmaceuticals, Inc. TFFP | Lytton, Laurence W. | 125,506 8.800% | 125,506 (New Position) | Filing History |
| 2022-05-20 6:45 pm Purchase | 2022-05-11 | 13G | EMCORE Corporation EMKR | Lytton, Laurence W. | 204,390 5.400% | 139,112 (+213.10%) | Filing History |
| 2022-05-18 4:47 pm Purchase | 2022-05-09 | 13G | Paratek Pharmaceuticals, Inc. PRTK | Lytton, Laurence W. | 3,210,552 5.900% | 3,210,552 (New Position) | Filing History |
| 2022-03-30 12:48 pm Purchase | 2022-03-02 | 13G | Scientific Industries, Inc. SCND | Lytton, Laurence W. | 408,229 5.700% | 408,229 (New Position) | Filing History |
| 2022-03-04 5:23 pm Purchase | 2022-02-22 | 13G | Crescent Biopharma, Inc. CBIO | Lytton, Laurence W. | 4,726 5.900% | 4,430 (+1493.26%) | Filing History |